Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer

Stanley C. Hopkins; Genaro M. Palmieri; Harvey B. Niell; Mohammad Moinuddin; Mark S. Soloway

doi:10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0

Total and nondialyzable hydroxyproline excretion in stage D₂ prostate cancer

Stanley C. Hopkins, Genaro M. Palmieri, Harvey B. Niell, Mohammad Moinuddin, Mark S. Soloway

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D₂ prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

Original language	English (US)
Pages (from-to)	117-121
Number of pages	5
Journal	Cancer
Volume	53
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0
State	Published - Jan 1 1984
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0

Cite this

@article{fe3baebcca484a10ad7ef86d6ed98760,

title = "Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer",

abstract = "Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.",

author = "Hopkins, {Stanley C.} and Palmieri, {Genaro M.} and Niell, {Harvey B.} and Mohammad Moinuddin and Soloway, {Mark S.}",

year = "1984",

month = jan,

day = "1",

doi = "10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0",

language = "English (US)",

volume = "53",

pages = "117--121",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer

AU - Hopkins, Stanley C.

AU - Palmieri, Genaro M.

AU - Niell, Harvey B.

AU - Moinuddin, Mohammad

AU - Soloway, Mark S.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

AB - Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

UR - http://www.scopus.com/inward/record.url?scp=0021353141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021353141&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0

DO - 10.1002/1097-0142(19840101)53:1<117::AID-CNCR2820530121>3.0.CO;2-0

M3 - Article

C2 - 6689994

AN - SCOPUS:0021353141

VL - 53

SP - 117

EP - 121

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -

Total and nondialyzable hydroxyproline excretion in stage D₂ prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this